Share This Page
Drug Price Trends for HM DUAL ACTION COMPLETE TB CHW
✉ Email this page to a colleague

Average Pharmacy Cost for HM DUAL ACTION COMPLETE TB CHW
Drug Name | NDC | Price/Unit ($) | Unit | Date |
---|---|---|---|---|
HM DUAL ACTION COMPLETE TB CHW | 62011-0276-01 | 0.25562 | EACH | 2025-01-22 |
HM DUAL ACTION COMPLETE TB CHW | 62011-0276-01 | 0.25773 | EACH | 2024-12-18 |
HM DUAL ACTION COMPLETE TB CHW | 62011-0276-01 | 0.26193 | EACH | 2024-11-20 |
HM DUAL ACTION COMPLETE TB CHW | 62011-0276-01 | 0.26148 | EACH | 2024-10-23 |
HM DUAL ACTION COMPLETE TB CHW | 62011-0276-01 | 0.25316 | EACH | 2024-09-18 |
HM DUAL ACTION COMPLETE TB CHW | 62011-0276-01 | 0.25359 | EACH | 2024-08-21 |
>Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Tuberculosis Treatment Drugs
Introduction
Tuberculosis (TB) is a significant global health issue, and the market for TB treatment drugs is evolving to address the growing need for effective and accessible treatments. This analysis will focus on the market dynamics, trends, and price projections for TB treatment drugs, rather than a specific product like "HM DUAL ACTION COMPLETE TB CHW," which does not appear to be a real or recognized TB treatment drug.
Global TB Treatment Drugs Market Size and Growth
The global tuberculosis treatment drugs market was valued at $1.9 billion in 2021 and is projected to reach $3.2 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 5.3% from 2022 to 2031[3].
Market Segmentation
By Disease Type
The market is categorized into active TB and latent TB. The active TB segment accounted for the largest share in 2021 due to the rising prevalence of TB cases globally. However, the latent TB segment is expected to witness the highest CAGR during the forecast period, driven by government initiatives and increased awareness about the risks associated with untreated latent TB[3].
By Therapy
The market is divided into first-line therapy and second-line therapy. First-line therapy dominated the market in 2021 due to its high effectiveness and widespread use in combination with other antibiotics. Second-line therapy is expected to grow significantly due to the increasing prevalence of drug-resistant TB[3].
By Distribution Channel
The market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Drug stores and retail pharmacies held the largest market share in 2021 and are expected to remain dominant, while online providers are projected to register the highest CAGR due to the rising popularity of online pharmacies[3].
Regional Analysis
The TB treatment drugs market is analyzed across North America, Europe, Asia-Pacific, and Latin America, Middle East, and Africa (LAMEA). North America accounted for the largest market share in 2021 and is expected to remain dominant, driven by higher healthcare awareness, early detection of TB cases, and the presence of trained medical professionals. The Asia-Pacific region is anticipated to witness notable growth due to the higher prevalence of TB and rising awareness for early detection[3].
Market Drivers
- Increasing Prevalence of TB: The rise in TB cases, particularly drug-resistant TB, is driving the demand for effective anti-TB drugs[3].
- Government Initiatives: Favorable government initiatives and increased investments in healthcare infrastructure are boosting the market[3].
- R&D and Novel Medications: Growth in pharmaceutical innovations and the approval of new anti-TB agents are positively impacting market growth[3].
Market Restraints
- Side Effects of Anti-TB Drugs: The side effects associated with anti-TB drugs are a significant restraint on market growth[3].
- Lack of Favorable Reimbursement Policies: The absence of favorable reimbursement policies is another constraint[3].
Price Projections
The prices of TB treatment drugs are influenced by several factors, including the cost of production, regulatory approvals, market competition, and government policies.
First-Line Therapy
First-line therapy drugs, which are the most commonly used, are generally less expensive due to their widespread use and availability. However, prices can vary significantly depending on the region and the specific drug formulation.
Second-Line Therapy
Second-line therapy drugs, used for drug-resistant TB, are typically more expensive due to the complexity of their formulation and the longer treatment duration. The cost can range from several thousand to tens of thousands of dollars per treatment course, depending on the specific drugs and the duration of treatment[1][3].
Illustrative Statistics
- In 2019, the global treatment success rate for people with multidrug-resistant TB (MDR-TB) was 57%[1].
- The number of people enrolled in MDR-TB treatment in 2019 was only 38% of the estimated number of people who developed MDR-TB, highlighting a significant gap in treatment access[1].
Expert Insights
"TB impedes development; at the same time, poverty, vulnerability, and other social factors fuel TB. Success depends on action across sectors," emphasizes the World Health Organization (WHO) in its Global TB Report 2020. This underscores the need for a multisectoral approach to combat TB effectively[1].
Key Takeaways
- The global TB treatment drugs market is growing, driven by increasing prevalence and government initiatives.
- First-line therapy dominates the market, but second-line therapy is expected to grow significantly due to drug resistance.
- Regional variations in market size and growth are influenced by healthcare infrastructure and awareness.
- Side effects and lack of reimbursement policies are key restraints.
- Prices vary widely depending on the type of therapy and regional factors.
Frequently Asked Questions
1. What is the current size of the global TB treatment drugs market?
The global TB treatment drugs market was valued at $1.9 billion in 2021[3].
2. What is the projected growth rate of the TB treatment drugs market?
The market is projected to grow at a CAGR of 5.3% from 2022 to 2031[3].
3. Which segment dominates the TB treatment drugs market?
The active TB segment currently dominates the market, but the latent TB segment is expected to witness the highest CAGR during the forecast period[3].
4. What are the main drivers of the TB treatment drugs market?
The main drivers include the increasing prevalence of TB, government initiatives, and growth in pharmaceutical innovations[3].
5. What are the significant restraints on the TB treatment drugs market?
The significant restraints include the side effects of anti-TB drugs and the lack of favorable reimbursement policies[3].
Cited Sources:
- World Health Organization. Global Tuberculosis Report 2020.
- Allied Market Research. Tuberculosis Treatment Drugs Market Statistics | Forecast - 2031.
More… ↓